Radius Health

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. As a science-driven biopharmaceutical company, we are focused on developing medicines that will have a meaningful impact on patients’ lives. We are excited to have both a Marketing Authorization Application (MAA) in Europe and a New Drug Application (NDA) in the United States under regulatory review for the investigational drug, abaloparatide for subcutaneous administration, for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Also in development is the investigational abaloparatide transdermal patch for potential use in osteoporosis. Additionally, we have the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, as well as vasomotor symptoms in postmenopausal women. Our preclinical pipeline includes the early stage candidate, RAD140, a non-steroidal, selective androgen receptor modulator for potential use in multiple applications. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.

Type
Public
HQ
Waltham, US
Founded
2003
Size (employees)
229 (est)
Radius Health was founded in 2003 and is headquartered in Waltham, US

Key People at Radius Health

Michael Wyzga

Michael Wyzga

President & CEO
Gary Hattersley

Gary Hattersley

Senior Vice President, Preclinical Development
Michael Franken

Michael Franken

Senior Vice President, Chief Business Officer

Radius Health Office Locations

Radius Health has an office in Waltham
Waltham, US (HQ)
950 Winter St

Radius Health Data and Metrics

Radius Health Financial Metrics

USD

Net income (FY, 2015)

(101.5 m)

EBIT (FY, 2015)

(99.1 m)

Market capitalization (25-May-2017)

1.6 b

Closing share price (25-May-2017)

37.4

Cash (31-Dec-2016)

258.6 m
Radius Health's current market capitalization is $1.6 b.
USDFY, 2013FY, 2014FY, 2015

EBIT

(67.4 m)(59.4 m)(99.1 m)

Net Income

(60.7 m)(62.5 m)(101.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.3 m258.6 m

Inventories

334 k2.3 m

Current Assets

12.6 m334.8 m

PP&E

76 k4.9 m

Total Assets

12.8 m340.3 m

Accounts Payable

300 k6.1 m

Current Liabilities

35.3 m32.7 m

Preferred Stock

43.9 m

Additional Paid-in Capital

935.7 m

Retained Earnings

(277.3 m)(628.6 m)

Total Equity

(277.3 m)307.2 m

Financial Leverage

0 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(60.7 m)(101.5 m)(182.8 m)

Depreciation and Amortization

27 k586 k

Inventories

1.7 m2.1 m7 m4.6 m

Accounts Payable

(250 k)2.3 m6.2 m(100 k)

Cash From Operating Activities

(45 m)16.2 m131.2 m(139.8 m)

Purchases of PP&E

(2 k)(2.9 m)

Cash From Investing Activities

4 m236.1 m

Cash From Financing Activities

34.7 m2.6 m

Interest Paid

1.8 m
Y, 2016

Financial Leverage

1.1 x

Radius Health Market Value History

Radius Health Online and Social Media Presence

Radius Health News and Updates

Radius Health Company Life and Culture

You may also be interested in